<?xml version="1.0" encoding="UTF-8"?><CAS version="2"><uima.cas.Sofa _indexed="0" _id="1" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="P07918128A0000 BACKGROUND: We conducted a phase I study with MDL 73,147EF, a new 5 hydroxytryptamine 3 (5-HT3) receptor antagonist, in 25 patients requiring emetogenic chemotherapy."/><uima.tcas.DocumentAnnotation _indexed="1" _id="8" _ref_sofa="1" begin="0" end="181" language="x-unspecified"/></CAS>